Get started
Author

Ana Fuentes Coronel

Observed names: A Fuentes Coronel, A M Coronel, A M Fuentes Coronel, A. Fuentes Coronel, A. M. Fuentes Coronel, Ana M Coronel, Ana Maria Fuentes Coronel, Ana María Fuentes Coronel, Ana María Fuentes Coronel, Fuentes Coronel, A.M.
ORCID: 0000-0001-8862-0922
Observed ORCID: 0000-0001-8862-0922
OpenAlex ID: A5020852394
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
2021 · María Chaparro, Ana Garre, et al. · Journal of Clinical Medicine · 106
Atrichia, ichthyosis, follicular hyperkeratosis, chronic candidiasis, keratitis, seizures, mental retardation and inguinal hernia: a severe manifestation of IFAP syndrome?
2000 · M C Boente, H Bibas-Bonet, et al. · PubMed · 25
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
2024 · Carla J. Gargallo-Puyuelo, Elena Ricart, et al. · Clinical Gastroenterology and Hepatology · 24
PDF
IFAP syndrome “plus” seizures, mental retardation, and callosal hypoplasia
2001 · Hilda Bibas-Bonet, Ricardo Fauze, et al. · Pediatric Neurology · 24
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
2022 · Yamile Zabana, Ignacio Marín-Jiménez, et al. · Journal of Clinical Medicine · 13
Hematoma hepático subcapsular secundario al empleo de una guía hidrofílica durante una colangiopancreatografía retrógrada endoscópica
2008 · Carlos de la Serna-Higuera, Ana Fuentes Coronel, et al. · Gastroenterología y Hepatología · 13
Cutis tricolor coexistent with cutis marmorata telangiectatica congenita: "phacomatosis achromico-melano-marmorata".
2008 · María del C Boente, Roxana Obeid, et al. · PubMed · 12
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
2024 · Rocío Ferreiro‐Iglesias, Sol Porto Silva, et al. · Alimentary Pharmacology & Therapeutics · 11
Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA
2025 · Cristina Rubín de Célix, Elena Ricart, et al. · Alimentary Pharmacology & Therapeutics · 8
A clinical trial comparing propofol versus propofol plus midazolam in diagnostic endoscopy of patients with a low anesthetic risk
2018 · Laura Julián Gómez, Ana Fuentes Coronel, et al. · Revista Española de Enfermedades Digestivas · 8
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence
2024 · Antonio Giordano, Isabel Pérez-Martínez, et al. · The American Journal of Gastroenterology · 7
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study
2024 · Patricia Sanz Segura, Fernando Gomollón, et al. · Digestive and Liver Disease · 5
PDF
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
2022 · Yamile Zabana, Ignacio Marín-Jiménez, et al. · Journal of Clinical Medicine · 4
PDF
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885
2022 · María Chaparro, Ana Garre, et al. · Journal of Clinical Medicine · 4
Incidencia e historia natural de la enfermedad inflamatoria intestinal en Castilla y León: estudio prospectivo, multicéntrico y poblacional
2022 · Rosa María Sáiz-Chumillas, Jesús Barrio, et al. · Gastroenterología y Hepatología · 3
P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc
2022 · M Garcia-Alvarado, J Barrio, et al. · Journal of Crohn s and Colitis · 3
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
2021 · Carlos Taxonera, María Pilar Martínez-Montiel, et al. · Therapeutic Advances in Gastroenterology · 3
Hemorragia gastrointestinal recurrente por hemangioma mesentérico con afección del intestino delgado
2002 · Ana Maria Fuentes Coronel, Antonio Rodríguez Pérez, et al. · Medicina Clínica · 3
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry
2025 · Míriam Mañosa, Margalida Calafat, et al. · United European Gastroenterology Journal · 2
PDF
Incidence, and natural history of inflammatory bowel disease in Castilla y León:Prospective and multicenter epidemiological study
2023 · Rosa María Sáiz-Chumillas, Jesús Barrio, et al. · Gastroenterología y Hepatología (English Edition) · 2
Granulomatous appendicitis as an uncommon cause of abdominal pain. Description of a case
2015 · Carmen Salvia López Ramos, Ana Fuentes Coronel, et al. · Revista Española de Enfermedades Digestivas · 2
Uveítis anterior en paciente tratada con interferón pegilado y ribavirina
2003 · José Antonio Carneros Martín, Ana Fuentes Coronel, et al. · Medicina Clínica · 2
Factores Predictores Del Uso De Tratamientos Biológicos O Pequeñas Moléculas, Cirugías Y Hospitalizaciones En Una Cohorte De Pacientes Recién Diagnosticados De Eii: Resultados a Largo Plazo Del Estudio Epidemibd De Geteccu
2025 · Ana Garre Vázquez, Andrea Núñez Ortiz, et al. · Gastroenterología y Hepatología · 1
DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
2024 · C Rubín De Célix, E Ricart, et al. · Journal of Crohn s and Colitis · 1
PDF
Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
2021 · Y Zabana Abdo, I Marín-Jiménez, et al. · Journal of Crohn s and Colitis · 1
PDF
Works count: 40
Citation count: 289
H-index: 8
I10-index: 8
Year
Topic
Type